Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis.

摘要: The value of targeting VEGFR (vascular endothelial growth factor receptor) drugs has demonstrated encouraging anti-cancer activity in advanced solid tumors within current clinical trials. This study aimed to serve as the first systemic review assess their safety and efficacy according biochemical characteristics gastric cancer. We analyzed eight trials on Results showed that significantly improved overall survival (OS) [Hazard Ratio (HR) 0.69, 95% confidence interval (CI) (0.55, 0.83), P < 0.001], progression free (PFS) [HR 0.50, CI (0.34, 0.66), disease control rate (DCR) [Odds (OR) 3.83, (2.39, 6.15), 0.001] decreased progressive rate(PDR)[OR 0.45, 0.59), but not objective response (ORR) [OR 1.46, (0.93, 2.29), = 0.098]. Further subgroup revealed antibody (VEGFR-Ab) were superior tyrosine kinase inhibitor (VEGFR-TKI) terms OS, PFS PDR. To determine toxic effect drugs, relative risk adverse events (grade ≥ 3) special interest(AESIs) estimated. Most these predictable manageable. Furthermore, less AESIs observed VEGFR-Ab than VEGFR-TKI drugs. In conclusion, effective targeted therapy or metastatic cancer, its toxicity is a controllable range. more PDR cancer patients with little toxicity.